Monitor upcoming sBLA submission for lifileucel in 2L mNSCLC in 2027 and the OPTILISM Phase 3 trial initiation, as NSCLC represents a 10x larger opportunity than the current melanoma market. The raised guidance and strong Q3 revenue growth (~80% YoY) suggest accelerating commercial adoption of Amtagvi.
Drugs in focus
IOVA drug pipeline →Amtagvi
● Neutral Named in this 8-K- Impact
- Phase
- Approved (accelerated approval)
- Time to market
- Already approved and marketed (FDA accelerated approval Feb 16, 2024). Confirmatory Phase 3 (TILVANCE-301) is ongoing to convert to full approval.
- Next catalyst
- BLA filing · 2027
What to watchWatch for TILVANCE-301 Phase 3 interim or topline results (undated but the key catalyst for converting accelerated to full approval and expanding into frontline) and quarterly revenue growth trajectory, Q2 2026 guidance is $86M-$88M. Also monitor IOV-LUN-202 NSCLC registrational data (Fast Track, potential launch 2H27). At ~$3.97 with a mean analyst target of $8.80 (177% upside), the stock prices in meaningful commercial execution but not a TILVANCE-301 success.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+5- T+0 · Nov 6 $8.04entry
- T+1 · 8d ago +1.62%α −0.75% · $8.17
- T+5 · 4d ago −3.48%α −6.08% · $7.76
- T+6 · todayOpen
- T+20 · in 20d Pending
- T+60 · in 3mo Pending
Price Chart
How similar events traded
Executive Summary
Iovance Biotherapeutics filed an 8-K to update its corporate presentation, which includes a raised full-year 2026 revenue guidance from $350M-$370M to $410M-$420M (midpoint increase of ~15%), reported Q3 2026 revenue of ~$122M (~80% YoY growth), and disclosed interim clinical data across its TIL pipeline including NSCLC and sarcoma programs. The filing is a routine business update with no material new corporate events.
Key Facts
- Full year 2026 revenue guidance raised from $350M-$370M to $410M-$420M, a ~15% midpoint increase of $55M
- Q3 2026 revenue of ~$122M, representing ~80% year-over-year growth and ~22% sequential growth
- Q3 2026 margin from cost of sales (excl. D&A) of ~60%, 54% year-to-date
- Cash, cash equivalents, short-term investments and restricted cash of ~$382M as of September 30, 2026, with runway well into 2029
- Interim data from IOV-LUN-202 in non-squamous NSCLC showed 24.6% ORR (17/69) and 59.1% ORR (13/22) in a biomarker-enriched population
- Interim data from SARATOGA in soft tissue sarcomas showed 55.6% ORR (5/9) in DDLPS and UPS
- First 5 evaluable patients in ENDURANCE endometrial cancer trial showed 40% ORR and 100% DCR
- Planned sBLA submission for lifileucel in 2L mNSCLC in 2027; OPTILISM Phase 3 trial in frontline NSCLC to start in 2027
- Over 100 authorized treatment centers in U.S., Canada and Australia; over 1,000 commercial patients treated
Financial Impact
FY26 revenue guidance raised by ~$55M at midpoint to $410M-$420M; Q3 revenue ~$122M; cash ~$382M
Risk Factors
- Clinical trial results are interim and may not be confirmed in final analyses or support regulatory approvals
- Forward-looking statements and guidance are subject to risks including manufacturing, payor coverage, and competitive dynamics
- The company is not yet profitable and may not generate sufficient revenue to achieve profitability
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-450084 |
| Document: iova-20261105.htm | 0001193125-26-450084 |
| Document: 0001193125-26-450084-index-headers.html | 0001193125-26-450084 |
| Document: 0001193125-26-450084-index.html | 0001193125-26-450084 |
| Document: 0001193125-26-450084.txt | 0001193125-26-450084 |
Track record
21 reports on IOVA
3 of 4 bullish or bearish reports moved the stock their way by T+20. Best: +121.97% at T+60 after the Jun 10, 2026 report. 5 of 7 went positive at some point.
Filters
- Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $8.08 Now $7.55 −6.56% settles Dec 9
- Nov 5, 202611d ago 8-K Neutral 4/10 Viewing Entry $8.04 Now $7.55 −6.09% settles Dec 7
- Nov 5, 202611d ago 8-K Bullish 6/10 Entry $7.74 Now $7.55 −2.45% settles Dec 4
- Nov 3, 202613d ago Institutional Cluster Neutral 3/10 Entry $8.70 Now $7.55 −13.22% settles Dec 3
- Oct 29, 202618d ago 8-K Bullish 6/10 Entry $8.48 Now $7.55 −10.97% settles Nov 30
- Oct 28, 202619d ago Press Release Bullish 7/10 Entry $9.56 Now $7.55 −21.03% settles Nov 27
- Oct 5, 20266w ago 8-K Neutral 4/10 Entry $12.96 to $8.65 Now $7.55 −41.74% ▼ −33.25% −30.34% vs SPY
- Oct 2, 20266w ago 3 Neutral 2/10 Entry $14.15 to $7.93 Now $7.55 −46.64% ▼ −43.99% −41.42% vs SPY
- Sep 29, 20266w ago 8-K Bullish 6/10 Entry $14.45 to $14.58 Now $7.55 −47.75% ▲ +0.90% +0.19% vs SPY
- Aug 21, 202612w ago Press Release Neutral 2/10 Entry $8.06 to $10.64 Now $7.55 −6.33% ▲ +32.01% +30.70% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers